MLMC Therapeutics ApS: Financial statements 2022
CVR: 41277688
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
MLMC Therapeutics ApS (CVR 41277688) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -29,822 and a net result of DKK -90,240 compared with DKK -53,670 the year before. Equity in the 2022 report amounted to DKK -81,871.
- Gross Profit
- DKK -29,822
- Profit/Loss
- DKK -90,240
- Equity
- DKK -81,871
- Total Assets
- DKK 220,116
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -30 t. | -90 t. | -82 t. | - |
| 2021 | - | -20 t. | -54 t. | 8 t. | 0 |
Official annual report
Keep an eye on MLMC Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of June 15, 2022, A/S PSE 17 NR. 1056 has been appointed auditor of MLMC Therapeutics ApS.
As of June 15, 2022, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of MLMC Therapeutics ApS.
MLMC Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -19,909, and the net result was DKK -53,670.
About MLMC Therapeutics ApS
MLMC Therapeutics ApS is a Danish company of the type Anpartsselskab based in Kastrup, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Michael Henrik Stadi. The board consists of Martin Kiener (chair), Hanne Damgaard Jensen and Peter Gudmund Nielsen. The company's owners include Ritika Singh Petersen, Sriram Thoppe Rajendran and FOMT HOLDING ApS. According to the 2021 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -30,768 and a net result of DKK -144,214 compared with DKK -134,525 the year before. Equity in the 2025 report amounted to DKK -483,287.